<bill session="113" type="s" number="2134" updated="2016-10-25T16:29:19Z">
  <state datetime="2014-03-13">REFERRED</state>
  <status>
    <introduced datetime="2014-03-13"/>
  </status>
  <introduced datetime="2014-03-13"/>
  <titles>
    <title type="short" as="introduced">Act to Ban Zohydro</title>
    <title type="official" as="introduced">A bill to withdraw approval for the drug Zohydro ER and prohibit the Food and Drug Administration from approving such drug unless it is reformulated to prevent abuse.</title>
    <title type="display">Act to Ban Zohydro</title>
  </titles>
  <sponsor bioguide_id="M001183"/>
  <cosponsors/>
  <actions>
    <action datetime="2014-03-13">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2014-03-13" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="SSHR" name="Senate Health, Education, Labor, and Pensions" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="h" session="113" relation="identical" number="4241"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Drug, alcohol, tobacco use"/>
  </subjects>
  <amendments/>
  <summary date="2014-03-13T04:00:00Z" status="Introduced in Senate">Act to Ban Zohydro - Ends the sale and distribution of pure hydrocodone bitartrate extended-release capsules (marketed as Zohydro ER) within 45 days by withdrawing approval for its new drug application. Prohibits the Commissioner of Food and Drugs (FDA) from approving any new drug application for the capsules unless they are formulated to prevent abuse.</summary>
  <committee-reports/>
</bill>
